REG - Mediclinic Intnl plc - Form 8 (DD) - Mediclinic International plc

Mediclinic InternationalAnnouncement

25/05/2023 14:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230525:nRSY6897Aa&default-theme=true

RNS Number : 6897A  Mediclinic International plc  25 May 2023

Mediclinic International plc

(Incorporated in England and Wales)

Company Number: 08338604

LSE Share Code: MDC

JSE Share Code: MEI

NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

South African income tax number: 9432434182

('Mediclinic', the 'Company', or the 'Group')

 

25 May 2023

 

FORM 8 (DD)

 

PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT
(INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS)

Rules 8.1, 8.2 and 8.4 of the Takeover Code (the 'Code')

 

1.         KEY INFORMATION

 

 (a) Full name of discloser:                                                     Petrus Jurgens Myburgh
 (b) Owner or controller of interests and short positions disclosed, if          N/A
 different from 1(a):

      The naming of nominee or vehicle companies is insufficient.  For a
 trust, the trustee(s), settlor and beneficiaries must be named.
 (c) Name of offeror/offeree in relation to whose relevant securities this form  Mediclinic International plc
 relates:

      Use a separate form for each offeror/offeree
 (d) Status of person making the disclosure:                                     Person acting in concert with the offeree (Mediclinic International plc)

      e.g. offeror, offeree, person acting in concert with the
 offeror/offeree (specify name of offeror/offeree)
 (e) Date dealing undertaken:                                                    24 May 2023
 (f)  In addition to the company in 1(c) above, is the discloser making          N/A
 disclosures in respect of any other party to the offer?

      If it is a cash offer or possible cash offer, state "N/A"

 

2.         POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one
class of relevant securities of the offeror or offeree named in 1(c), copy
table 2(a) or (b) (as appropriate) for each additional class of relevant
security.

 

(a)        Interests and short positions in the relevant securities of
the offeror or offeree to which the disclosure relates following the dealing

 

 Class of relevant security:

                                                                      Interests             Short positions

                                                                      Number       %((1))   Number    %
 (1) Relevant securities owned and/or controlled:                     94 500((2))  0.0128%  Nil       Nil
 (2) Cash-settled derivatives:                                        Nil          Nil      Nil       Nil

 (3) Stock-settled derivatives (including options) and agreements to  Nil          Nil      Nil       Nil
 purchase/sell:
                                                                      94 500       0.0128%  Nil       Nil

      TOTAL:

 

((1)) Total number of ordinary shares of Mediclinic International plc is 737
243 810 as of 24 May 2023. The percentages have been rounded to the four
nearest decimal places.

( )

((2)) Petrus Jurgens Myburgh owns 94 500 ordinary shares.

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded
options), or agreements to purchase or sell relevant securities, should be
given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial
collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b)        Rights to subscribe for new securities (including directors'
and other employee options)

 

 Class of relevant security in relation to which subscription right exists:   N/A
 Details, including nature of the rights concerned and relevant percentages:  N/A

 

 

3.         DEALINGS BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities
of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as
appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a)        Purchases and sales

 

(i)         Party to an offer or person acting in concert (except for
a principal trader in the same group as a connected adviser)

 

 Class of relevant security  Purchase/sale  Number of securities  Price per unit

 N/A                         N/A            N/A                   N/A

 

(ii)        Principal trader where the sole reason for the connection
is that the principal trader is in the same group as a connected adviser

 

 Class of relevant security  Purchases/ sales  Total number of securities  Highest price per unit paid/received  Lowest price per unit paid/received

 N/A                         N/A               N/A                         N/A                                   N/A

 

(b)        Cash-settled derivative transactions

 

 Class of relevant security  Product description  Nature of dealing                                                              Number of reference securities  Price per unit

                             e.g. CFD             e.g. opening/closing a long/short position, increasing/reducing a long/short
                                                  position
 N/A                         N/A                  N/A                                                                            N/A                             N/A

 

(c)        Stock-settled derivative transactions (including options)

 

(i)         Writing, selling, purchasing or varying

 

 Class of relevant security  Product description e.g. call option  Writing, purchasing, selling, varying etc.  Number of securities to which option relates  Exercise price per unit  Type                           Expiry date  Option money paid/ received per unit

                                                                                                                                                                                      e.g. American, European etc.
 N/A                         N/A                                   N/A                                         N/A                                           N/A                      N/A                            N/A          N/A

 

(ii)        Exercise

 

 Class of relevant security  Product description  Exercising/ exercised against  Number of securities  Exercise price per unit

                             e.g. call option
  N/A                         N/A                  N/A                            N/A                   N/A

 

(d)        Other dealings (including subscribing for new securities)

 

 Class of relevant security                                     Nature of dealing                                                        Details                                                                          Price per unit (if applicable)

                                                                e.g. subscription, conversion
 Mediclinic International plc ordinary shares of 10 pence each  Vesting of awards granted under the Company's Short Term Incentive Plan  Vesting and cash settlement of awards over 128 143 ordinary shares in the        N/A
                                                                                                                                         Company under the Company's Short Term Incentive Plan following the
                                                                                                                                         sanctioning of the scheme of arrangement in relation to the recommended cash
                                                                                                                                         offer for the Company. Those awards will be settled in cash for 501 pence per
                                                                                                                                         share in accordance with the rules of the Short Term Incentive Plan.
 Mediclinic International plc ordinary shares of 10 pence each  Vesting of awards granted under the Company's Long Term Incentive Plan   Vesting and cash settlement of awards over 216 953 ordinary shares in the        N/A
                                                                                                                                         Company under the Company's Long Term Incentive Plan following the sanctioning
                                                                                                                                         of the scheme of arrangement in relation to the recommended cash offer for the
                                                                                                                                         Company. Those awards will be settled in cash for 501 pence per share in
                                                                                                                                         accordance with the rules of the Long Term Incentive Plan.

 

 

4.         OTHER INFORMATION

 

(a)        Indemnity and other dealing arrangements

 

 Details of any indemnity or option arrangement, or any agreement or
 understanding, formal or informal, relating to relevant securities which may
 be an inducement to deal or refrain from dealing entered into by the party to
 the offer or person acting in concert making the disclosure and any other
 person:

 Irrevocable commitments and letters of intent should not be included.  If
 there are no such agreements, arrangements or understandings, state "none"

 None.

 

(b)        Agreements, arrangements or understandings relating to
options or derivatives

 

 Details of any agreement, arrangement or understanding, formal or informal,
 between the party to the offer or person acting in concert making the
 disclosure and any other person relating to:

 (i)  the voting rights of any relevant securities under any option; or

 (ii) the voting rights or future acquisition or disposal of any relevant
 securities to which any derivative is referenced:

 If there are no such agreements, arrangements or understandings, state "none"

 None.

 

(c)        Attachments

 

Are any Supplemental Forms attached?

 

 Supplemental Form 8 (Open Positions)  NO
 Supplemental Form 8 (SBL)             NO

 

 

 Date of disclosure:  25 May 2023
 Contact name:        Company Secretary, Link Company Matters Limited

                      Caroline Emmet
 Telephone number:    +44 (0)333 300 1930

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory
Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation
to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at
 www.thetakeoverpanel.org.uk.

 

 

 

 

CONTACT INFORMATION

 

Investor queries

James Arnold, Head of Investor Relations, Mediclinic International plc

+44 (0)20 3786 8181

 ir@mediclinic.com

 

Media queries

FTI Consulting

Ben Atwell/Ciara Martin - UK

+44 (0)20 3727 1000

Sherryn Schooling - South Africa

+27 (0)21 487 9000

 

Registered address: 6(th) Floor, 65 Gresham Street, London, EC2V 7NQ, United
Kingdom

Website:  www.mediclinic.com

Joint corporate brokers: Morgan Stanley & Co International plc and UBS
Investment Bank

JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank
Ltd)

NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DCCNKPBDBBKDBPB